717
Views
4
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

Angiotensin II receptor blocker combinations: From guidelines to clinical practice

Pages 73-81 | Received 21 Mar 2011, Accepted 09 Apr 2011, Published online: 10 Aug 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Peter Bramlage, Claudia Zemmrich, Reinhard Ketelhut, Wolf-Peter Wolf, Eva-Maria Fronk & Roland E Schmieder. (2013) Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Vascular Health and Risk Management 9, pages 475-483.
Read now

Articles from other publishers (3)

Pingjian Ding, Yiheng Pan, Quanqiu Wang & Rong Xu. (2022) Prediction and evaluation of combination pharmacotherapy using natural language processing, machine learning and patient electronic health records. Journal of Biomedical Informatics 133, pages 104164.
Crossref
Antonio Sicras-Mainar. (2013) Farmacoeconomía de olmesartán en combinaciones a dosis fijas para el tratamiento de la hipertensión arterial. Hipertensión y Riesgo Vascular 30, pages 35-43.
Crossref
Maciej Banach, Dagmara Hering, Krzysztof Narkiewicz, Michal Mysliwiec, Jacek Rysz & Jolanta Malyszko. (2012) Lipids, Blood Pressure, Kidney-what was New in 2012?. International Journal of Pharmacology 8:8, pages 659-678.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.